A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can develop following traumatic brain injury. Led by researchers at ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Our lab and others have shown that the activities of macrophages and fibroblasts are sensitive to matrix stiffness. Previously, we identified mechanosensitive transient receptor potential vanilloid 4 ...

This review examines the cardiovascular risks associated with cannabis, revealing its potential to cause severe heart health ...

Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially ...

Recently, the transient receptor potential (TRP) and pannexin-1 channels have been suggested to play a role in other experimental paradigms. Thus, the aim of this work is to investigate if these ...

"This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D.

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

Figure 4: Response of a model RE cell stimulated by a 5–Hz train of GABA A receptor IPSPs at different levels of membrane potential. Figure 5: Localized pattern of activity propagating through ...

Improved analytical techniques mean tiny amounts of endocrine disrupting compounds or PFAS can be found in many places. But ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...